Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2018: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
Outline of Final Research Achievements |
This work deals with the development of novel supramolecular drug for the treatments of neointimal lesions and aortic aneurysm in rats. Moreover, to evaluate the potentials in supramolecular drug as an anti-cancer agent, drug-effect tests were performed against a head and neck tumor model. Our findings suggest that the novel supramolecular drug achieves specific delivery of rapamycin to the rat abdominal aortic aneurysm, neointimal lesions, and solid tumor, and might contribute to establishing a drug therapy approach targeting both aortic diseases and malignant cancers.
|